5 Key Takeaways

• 1

  Cell and gene therapies have the potential to transform serious diseases but face challenges in access due to high costs and complex delivery.

• 2

  Industry leaders emphasize the need to reduce production costs and treat patients earlier to improve access to these therapies.

• 3

  Expanding delivery beyond specialist centers is crucial for increasing patient access to cell and gene therapies.

• 4

  Assessing the long-term value of therapies, rather than just their upfront costs, is essential for sustainable access.

• 5

  Collaboration among manufacturers, regulators, healthcare systems, payers, and patient advocates is necessary for improving therapy accessibility.